Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.4% - Here's Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report)'s stock price was up 7.4% during trading on Monday . The company traded as high as $20.31 and last traded at $20.95. Approximately 42,144 shares traded hands during trading, a decline of 84% from the average daily volume of 259,438 shares. The stock had previously closed at $19.50.

Analysts Set New Price Targets

DNTH has been the topic of a number of analyst reports. Guggenheim restated a "buy" rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Wedbush reaffirmed an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reissued a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $54.33.

Dianthus Therapeutics Stock Up 4.7 %

The stock has a market cap of $655.69 million, a PE ratio of -8.16 and a beta of 1.62. The firm's fifty day moving average price is $20.24 and its 200 day moving average price is $23.06.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating analysts' consensus estimates of ($0.85) by $0.04. The firm had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Large investors have recently modified their holdings of the business. R Squared Ltd acquired a new stake in Dianthus Therapeutics in the fourth quarter valued at approximately $26,000. KLP Kapitalforvaltning AS acquired a new position in Dianthus Therapeutics during the 4th quarter valued at approximately $33,000. KBC Group NV purchased a new position in shares of Dianthus Therapeutics in the fourth quarter worth $35,000. BNP Paribas Financial Markets acquired a new stake in Dianthus Therapeutics during the 4th quarter worth about $59,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Dianthus Therapeutics by 3,030.6% during the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock worth $70,000 after purchasing an additional 3,758 shares during the period. Institutional investors own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.